E Therapeutics (ETX)

 

ETX Share PerformanceMore

52 week high14.9000 06/06/16
52 week low7.0000 22/12/16
52 week change -5.6250 (-42.45%)
4 week volume1,094,038 28/04/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Director Deals - e-Therapeutics PLC (ETX)

Prof Trevor Jones, Non Executive Director, bought 59,400 shares in the company on the 12th May 2017 at a price of 8.25p. T...

Director/PDMR Shareholding

RNS Number: 0163G e-Therapeutics plc 23 May 2017 E-THERAPEUTICS PLC ("e-Therapeutics" or the "Company") NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES Oxford, UK, 23 May 2017 - e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that it rec...

Notice of Annual General Meeting and Annual Report

RNS Number: 5003E e-Therapeutics plc 08 May 2017 e-Therapeutics plc ('e-Therapeutics' or the 'Company') Notice of Annual General Meeting and Annual Report Oxford, UK, 8 May 2017 - e-Therapeutics plc (AIM: ETX) announces that its annual report and accounts for the year ended 31 January 2017, which includes the notice convening the Company's 2017 Annual G...

Director/PDMR Shareholding

RNS Number: 0295E e-Therapeutics plc 03 May 2017 E-THERAPEUTICS PLC ("e-Therapeutics" or the "Company") NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES Oxford, UK, 3 May 2017 - e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that o n 2 ...

e-Therapeutics operating losses rise

e-Therapeutics' operating losses rose to 16.3m in the year to the end of January - up from 11.55m. The figure included impair...

Final Results

RNS Number: 6492C e-Therapeutics plc 19 April 2017 e-Therapeutics plc Full Year Results 19 April 2017: e-Therapeutics plc (AIM: ETX, 'e-Therapeutics' or the 'Company' ), the drug discovery company, announces its full year results for the year ended 31 January 2017. Highlights Major review and reorganisation Board and management changes, with Malcolm Young an...

Notification of Full Year Results Date

RNS Number: 7316B e-Therapeutics plc 06 April 2017 e-Therapeutics plc ("e-Therapeutics" or the "Company") Notification of Full Year Results Date Oxford, UK - 6 April 2017 - e-Therapeutics plc (AIM: ETX), the drug discovery company, will announce its full year results for the year ended 31 January 2017 on Wednesday, 19 April 2017. -Ends- For more information, p...

New CEO Commences at e-Therapeutics

RNS Number: 7347B e-Therapeutics plc 06 April 2017 e-Therapeutics plc ("e-Therapeutics" or the "Company") Appointment of Chief Executive Officer Oxford, UK - 6 April 2017 - e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that further to the Company's announcement on 9 January 2017, Dr. Raymond Barlow has today assumed his posit...

Fundamental DataMore

EPS-4.91
Dividend yield0 %

Equity Research (ETX)

edison investment research
e-Therapeutics plc
05/05/2017
e-Therapeutics offers public market investors a unique opportunity to gain exposure to a proprietary, cutting-edge in silico drug discovery platform that has already attracted significant investment...
edison investment research
e-Therapeutics plc
16/01/2017
e-Therapeutics (ETX) has appointed a new CEO, Dr Raymond Barlow, who will join the company by 1 May 2017. He brings significant R&D and business development experience, which will be invaluable...
edison investment research
e-Therapeutics plc.
20/09/2016
e-Therapeutics (ETX) is focused on driving value in its discovery platform. Costs will be reduced as the 17 product candidates in discovery as of July 2016 have been cut to a core five. Cash of £19....

Latest discussion posts More

  • Q1 2017 blog update - ETX

    Q1 2017 blog weekly ETX chart update - notes under each chart: http://bonker99.com/Blogs
    10-Feb-2017
    Bonker
  • ETX chart

    http://bonker99.com/charts
    6-Feb-2017
    Bonker
  • Results

    RNS available at company's website. although seems to be missing in III ...
    22-Mar-2016
    nk1999

Users' HoldingsMore

Users who hold E Therapeutics also hold..
LLOYDS GRP.26%
ROCKHOPPER26%
RENEURON26%
RANGE RES.23%
PREMIER OIL19%

Codes & Symbols

ISINGB00B2823H99
SymbolsETX, LSE:ETX, ETX.L, ETX:LN, LON:ETX, XLON:ETX